Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
Volume 0.87M
Average 1.32M
EWTX Total Liabilities
Everything the company owes to creditors and other parties.
Edgewise Therapeutics, Inc.NASDAQ: EWTX
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 493.7% from a year ago
Total liabilities stood at $147.35M at the end of Q3 FY2026, up 493.7% from a year earlier and up 366.1% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.
Context
- Total liabilities amounted to 8.3% of total assets at the end of Q3 FY2026, up 4.0 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +493.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 30.35M USD
- Year-over-year change
- +9.9%
- 4-year CAGR
- +29.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.35M | +9.9% |
| FY2024 | 2024-12-31 | 27.6M | +30.2% |
| FY2023 | 2023-12-31 | 21.21M | +4.0% |
| FY2022 | 2022-12-31 | 20.39M | +87.9% |
| FY2021 | 2021-12-31 | 10.85M | — |
Total Liabilities vs competitors
How EWTX compares with its peers on the latest reported figures
- EWTX's Sep 2026 total liabilities of $147.35M is the 4th highest of the 10 companies compared; the peer median is $50.48M.
- Its year-over-year change of +493.7% is the highest of 10, against a peer median of -1.4%.
- Total liabilities amounts to 8.3% of total assets for EWTX, versus a peer median of 19.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.42B | +20.2% | +14.8% | 105.1% | |
| Mar 2026 | $1.67B | -27.9% | -7.0% | 52.7% | |
| Jun 2026 | $291.86M | +85.3% | +58.5% | 29.4% | |
| Sep 2026 | $147.35M | +493.7% | +14.2% | 8.3% | |
| Mar 2026 | $64.66M | -6.6% | +21.7% | 19.3% | |
| Mar 2026 | $50.48M | +94.9% | +63.5% | 24.2% | |
| Mar 2026 | $48.76M | -1.4% | +2.6% | 11.5% | |
| Mar 2026 | $48.4M | -14.8% | -2.5% | 10.9% | |
| Mar 2026 | $47.58M | +82.2% | +9.4% | 14.6% | |
| Mar 2026 | $22.32M | -37.3% | -11.2% | 14.3% | |
| Peer median (excluding EWTX) | $50.48M | -1.4% | +9.4% | 19.3% | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.57M | 21.99M | 86.1M | 41.67M | 61.15M |
| Short-term Investments | 265.22M | 329.95M | 232.3M | 428.5M | 468.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 8.6M | 5.31M | 13.28M |
| Total Current Assets | 283.77M | 357M | 327M | 475.48M | 543.39M |
| Property, Plant & Equipment (Net) | 912K | 9.85M | 12.69M | 11.07M | 9.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 548K | 251K | 348K | 262K | 0 |
| Total Non-current Assets | 1.46M | 10.1M | 13.04M | 11.33M | 9.22M |
| Total Assets | 285.23M | 367.1M | 340.04M | 486.82M | 552.6M |
| Account Payables | 3.84M | 6.11M | 4.03M | 5.58M | 6.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.8M | 4.03M | 5.7M | 10.06M | 12.43M |
| Total Current Liabilities | 10.52M | 16.59M | 16.77M | 23.86M | 27.37M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.98M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 329K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 329K | 3.8M | 4.43M | 3.74M | 2.98M |
| Total Liabilities | 10.85M | 20.39M | 21.21M | 27.6M | 30.35M |
| Common Stock | 5K | 6K | 7K | 9K | 10K |
| Retained Earnings | (76.96M) | (144.6M) | (244.76M) | (378.58M) | (546.37M) |
| Accumulated OCI | (514K) | (1.36M) | 99K | 420K | 677K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 274.38M | 346.72M | 318.83M | 459.22M | 522.26M |
| Total Debt | 0 | 4.41M | 5.41M | 4.74M | 3.99M |
| Net Debt | (15.57M) | (17.59M) | (80.68M) | (36.93M) | (57.16M) |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.